Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 2/20 | 0.48 |
| ▸ | NLRP3 | Q96P20 | 3/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | STAT3 | P40763 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | XBP1 | P17861 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.40 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.40 |
| ▸ | TERT | O14746 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13555455 | 1.00 | PTGS2 (0.48) | PTGS2NLRP3TDP1CYP2D6CYP2C9 | |
| SCHEMBL13555308 | 1.00 | PTGS2 (0.48) | PTGS2NLRP3TDP1CYP2D6CYP2C9 | |
| SCHEMBL18430325 | 0.81 | PTGS2 (0.42) | PTGS2NLRP3TDP1CYP2D6CYP2C9 | |
| SCHEMBL21807699 | 0.73 | PTGS2 (0.40) | PTGS2NLRP3TDP1CYP2D6CYP2C9 | |
| Telekin SCHEMBL29780465 | 0.68 | NLRP3 (0.51) | PTGS2NLRP3TDP1CYP2D6CYP2C9 | |
| Ivalin SCHEMBL27903663 | 0.67 | NLRP3 (0.63) | PTGS2NLRP3TDP1CYP2D6CYP2C9 | |
| Alloalantolactone SCHEMBL29934802 | 0.67 | NLRP3 (0.50) | PTGS2NLRP3TDP1CYP2D6CYP2C9 | |
| Alloalantolactone SCHEMBL30105635 | 0.67 | NLRP3 (0.50) | PTGS2NLRP3TDP1CYP2D6CYP2C9 | |
| SCHEMBL12620337 | 0.66 | MAPT (0.42) | PTGS2NLRP3TDP1CYP2D6CYP2C9 | |
| SCHEMBL13555309 | 0.66 | RECQL (0.37) | TDP1CYP3A4RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180028550-A1 | USE OF ALBIFLORIN OR PHARMACEUTICALLY ACCEPTABLE SALT FOR PREVENTION AND/OR TREATMENT OF IRRITABLE BOWEL SYNDROME | ZHANG ZUOGUANG (CN) | 2018-02-01 | — | — | US | claimed |
| EP-3263114-A1 | USE OF ALBIFLORIN OR PHARMACEUTICALLY ACCEPTABLE SALT FOR PREVENTION AND/OR TREATMENT OF IRRITABLE BOWEL SYNDROME | Zhang, Zuoguang (CN) | 2018-01-03 | — | — | EP | claimed |
| CN-107106587-A | The purposes of albiflorin or the prevention of its pharmaceutically acceptable salt and/or treatment IBS | 张作光 | 2017-08-29 | — | — | CN | claimed |
| US-9555055-B2 | Use of albiflorin and metabolites thereof | ZHANG ZUOGUANG (CN) | 2017-01-31 | — | — | US | claimed |
| EP-2491934-B1 | USE OF ALBIFLORIN FOR ANTI-DEPRESSION | ZHANG ZUOGUANG (CN) | 2016-03-09 | — | — | EP | claimed |
| US-9023817-B2 | Use of albiflorin for anti-depression | ZHANG ZUOGUANG (CN) | 2015-05-05 | — | — | US | claimed |
| US-20130316966-A1 | USE OF ALBIFLORIN AND METABOLITES THEREOF | ZHANG ZUOGUANG (CN) | 2013-11-28 | — | — | US | claimed |
| EP-2644198-A1 | ANTIANXIETY AND SLEEP DISORDER IMPROVING USE OF ALBIFLORIN OR METABOLITE THEREOF IN | Zhang, Zuoguang (CN) | 2013-10-02 | — | — | EP | claimed |
| US-20120270820-A1 | USE OF ALBIFLORIN FOR ANTI-DEPRESSION | ZHANG ZUOGUANG (CN) | 2012-10-25 | — | — | US | claimed |
| EP-2491934-A1 | USE OF ALBIFLORIN FOR ANTI-DEPRESSION | Zhang, Zuoguang (CN) | 2012-08-29 | — | — | EP | claimed |
| CN-122081422-A | Synthesis method of alpha-hydroxy ketone compound | — | 2026-05-26 | — | — | CN | disclosed |
| CN-110872264-B | Cis-tetrahydrobenzofuran compound containing Z, E-diene outside ring and synthesis method thereof | 河南师范大学 | 2023-01-24 | — | — | CN | disclosed |
| US-10350230-B2 | Use of albiflorin or pharmaceutically acceptable salt for prevention and/or treatment of irritable bowel syndrome | ZHANG ZUOGUANG (CN) | 2019-07-16 | — | — | US | disclosed |
| US-20180028550-A1 | USE OF ALBIFLORIN OR PHARMACEUTICALLY ACCEPTABLE SALT FOR PREVENTION AND/OR TREATMENT OF IRRITABLE BOWEL SYNDROME | ZHANG ZUOGUANG (CN) | 2018-02-01 | — | — | US | disclosed |
| EP-3263114-A1 | USE OF ALBIFLORIN OR PHARMACEUTICALLY ACCEPTABLE SALT FOR PREVENTION AND/OR TREATMENT OF IRRITABLE BOWEL SYNDROME | Zhang, Zuoguang (CN) | 2018-01-03 | — | — | EP | disclosed |
| EP-2644198-A1 | ANTIANXIETY AND SLEEP DISORDER IMPROVING USE OF ALBIFLORIN OR METABOLITE THEREOF IN | Zhang, Zuoguang (CN) | 2013-10-02 | — | — | EP | disclosed |
| CN-103179973-A | Use of albiflorin or metabolite thereof for resisting anxiety and improving sleep disorder | ZHANG ZUOGUANG | 2013-06-26 | — | — | CN | disclosed |
| US-20120270820-A1 | USE OF ALBIFLORIN FOR ANTI-DEPRESSION | ZHANG ZUOGUANG (CN) | 2012-10-25 | — | — | US | disclosed |
| EP-2491934-A1 | USE OF ALBIFLORIN FOR ANTI-DEPRESSION | Zhang, Zuoguang (CN) | 2012-08-29 | — | — | EP | disclosed |
| WO-2012068958-A1 | ANTIANXIETY AND SLEEP DISORDER IMPROVING USE OF ALBIFLORIN OR METABOLITE THEREOF IN | ZHANG ZUOGUANG (CN) | 2012-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10350230-B2 | Use of albiflorin or pharmaceutically acceptable salt for prevention and/or treatment of irritable bowel syndrome | ALPI, ALB, SLC10A2 | PTGS2 1492/4885NLRP3 2279/4885TDP1 4817/4885 |
| US-20180028550-A1 | USE OF ALBIFLORIN OR PHARMACEUTICALLY ACCEPTABLE SALT FOR PREVENTION AND/OR TREATMENT OF IRRITABLE BOWEL SYNDROME | ALPI, ALB, SLC10A2 | PTGS2 1492/4885NLRP3 2279/4885TDP1 4817/4885 |
| US-20120270820-A1 | USE OF ALBIFLORIN FOR ANTI-DEPRESSION | GAP43, ALB, GRM5 | PTGS2 709/4885NLRP3 2928/4885TDP1 3067/4885 |
| US-20130316966-A1 | USE OF ALBIFLORIN AND METABOLITES THEREOF | SQSTM1, ATG7, ATG13 | PTGS2 2609/4885NLRP3 733/4885TDP1 3344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.